Mehhh_老虎社区_美港股上老虎

2021-12-24

Mehhh

Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞公司的 Covid 药丸获得批准。投资者开始关注这只股票。</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698109374,"tweetId":"698109374","gmtCreate":1640312308524,"gmtModify":1640313673855,"author":{"id":3556756933727652,"idStr":"3556756933727652","authorId":3556756933727652,"authorIdStr":"3556756933727652","name":"458b6d98","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":246,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Mehhh</body></html>","htmlText":"<html><head></head><body>Mehhh</body></html>","text":"Mehhh","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698109374","repostId":1110395878,"repostType":4,"repost":{"id":"1110395878","kind":"news","pubTimestamp":1640310818,"share":"https://www.laohu8.com/m/news/1110395878?lang=zh_CN&edition=full","pubTime":"2021-12-24 09:53","market":"us","language":"en","title":"Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞公司的 Covid 药丸获得批准。投资者开始关注这只股票。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1110395878","media":"Barrons","summary":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over","content":"The Covid-19 pill is here, and it couldn’t have come at a better time.<blockquote>Covid-19 药丸来了，而且来得正是时候。</blockquote> The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.<blockquote>随着奥密克戎变种席卷美国，疫情在过去两周变得更加黑暗。随着大多数广泛使用的疗法都因变异而失效，病例数也在迅速攀升，医生和公共卫生官员越来越担心。</blockquote> The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.<blockquote>美国食品和药物管理局周三批准辉瑞公司（股票代码：PFE）的 Covid-19 药片 Paxlovid，这带来了一些希望。这种药丸只对高危人群开放，最初供应有限，但它会挽救生命。</blockquote> The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.<blockquote>这项授权对辉瑞公司来说是一次非同寻常的政变，这是辉瑞公司在疫情的第二个政变。据 FactSet 称，分析师预计辉瑞将在 2022 年销售价值 217 亿美元的该药物，尽管该公司现在表示明年将生产 1.2 亿个疗程的该药物，比之前的预测多 4000 万个疗程，这可能会推高这些估计。</blockquote> As Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.<blockquote>作为巴伦11 月份有人认为，Paxlovid 的成功进一步证明，该公司在 2019 年决定剥离除创新生物制药业务以外的所有业务是明智的。</blockquote> Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.<blockquote>投资者在购买重组后的辉瑞公司方面进展缓慢，但今年晚些时候他们很快赶上了。在今年11月之前的12个月里，辉瑞公司的股价落后于标普500指数，尽管它推出了新冠肺炎疫苗。然而，自 11 月初以来，辉瑞股价暴涨。此后，该股上涨了 36.4%，而标普500仅上涨了 1.6%。</blockquote> And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.<blockquote>根据 FactSet 的数据，该股仍然相对便宜，未来 12 个月的交易价格仅为预期市盈率的 9.8 倍，这比礼来公司 (LLY) 市盈率为 31.7 倍，强生公司 (JNJ) 市盈率为 16.1 倍。</blockquote> The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.<blockquote>本周辉瑞的好消息与默克 (MRK) 的坏消息相匹配。虽然 Covid-19 药片 molnupiravir 的早期数据导致疫苗库存走低，默克公司股价走高，但该药物的光芒已经消失，因为最新数据显示，它的疗效不如最初看起来那么好，而且安全性问题一直挥之不去。</blockquote> The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.<blockquote>美国食品和药物管理局（FDA）于本周四发布了莫努匹拉韦的紧急使用授权，此前一天，该授权发布了 Paxlovid 的紧急使用授权，但条款要严格得多。该授权允许莫努匹拉韦仅在其他 Covid-19 治疗（如 Paxlovid）无法获得或临床上不合适的情况下使用。该机构也不建议在怀孕期间使用该药物，并建议服用莫努匹拉韦的男性在之后至少三个月内使用避孕措施。</blockquote> Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.<blockquote>早些时候人们对莫努匹拉韦可能成为长期收入驱动力的希望正在消失。这种失望提醒人们默克在本十年结束前面临的挑战：Keytruda 失去了专利保护，Keytruda 是一款癌症药物，约占其收入的三分之一。默克一直在努力填补这一空白。莫努匹拉韦似乎不会对这一努力做出重大贡献。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞公司的 Covid 药丸获得批准。投资者开始关注这只股票。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.<blockquote>辉瑞公司的 Covid 药丸获得批准。投资者开始关注这只股票。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-12-24 09:53\n\n</h4>\n</header>\n<article>\nThe Covid-19 pill is here, and it couldn’t have come at a better time.<blockquote>Covid-19 药丸来了，而且来得正是时候。</blockquote> The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.<blockquote>随着奥密克戎变种席卷美国，疫情在过去两周变得更加黑暗。随着大多数广泛使用的疗法都因变异而失效，病例数也在迅速攀升，医生和公共卫生官员越来越担心。</blockquote> The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.<blockquote>美国食品和药物管理局周三批准辉瑞公司（股票代码：PFE）的 Covid-19 药片 Paxlovid，这带来了一些希望。这种药丸只对高危人群开放，最初供应有限，但它会挽救生命。</blockquote> The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.<blockquote>这项授权对辉瑞公司来说是一次非同寻常的政变，这是辉瑞公司在疫情的第二个政变。据 FactSet 称，分析师预计辉瑞将在 2022 年销售价值 217 亿美元的该药物，尽管该公司现在表示明年将生产 1.2 亿个疗程的该药物，比之前的预测多 4000 万个疗程，这可能会推高这些估计。</blockquote> As Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.<blockquote>作为巴伦11 月份有人认为，Paxlovid 的成功进一步证明，该公司在 2019 年决定剥离除创新生物制药业务以外的所有业务是明智的。</blockquote> Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.<blockquote>投资者在购买重组后的辉瑞公司方面进展缓慢，但今年晚些时候他们很快赶上了。在今年11月之前的12个月里，辉瑞公司的股价落后于标普500指数，尽管它推出了新冠肺炎疫苗。然而，自 11 月初以来，辉瑞股价暴涨。此后，该股上涨了 36.4%，而标普500仅上涨了 1.6%。</blockquote> And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.<blockquote>根据 FactSet 的数据，该股仍然相对便宜，未来 12 个月的交易价格仅为预期市盈率的 9.8 倍，这比礼来公司 (LLY) 市盈率为 31.7 倍，强生公司 (JNJ) 市盈率为 16.1 倍。</blockquote> The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.<blockquote>本周辉瑞的好消息与默克 (MRK) 的坏消息相匹配。虽然 Covid-19 药片 molnupiravir 的早期数据导致疫苗库存走低，默克公司股价走高，但该药物的光芒已经消失，因为最新数据显示，它的疗效不如最初看起来那么好，而且安全性问题一直挥之不去。</blockquote> The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.<blockquote>美国食品和药物管理局（FDA）于本周四发布了莫努匹拉韦的紧急使用授权，此前一天，该授权发布了 Paxlovid 的紧急使用授权，但条款要严格得多。该授权允许莫努匹拉韦仅在其他 Covid-19 治疗（如 Paxlovid）无法获得或临床上不合适的情况下使用。该机构也不建议在怀孕期间使用该药物，并建议服用莫努匹拉韦的男性在之后至少三个月内使用避孕措施。</blockquote> Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.<blockquote>早些时候人们对莫努匹拉韦可能成为长期收入驱动力的希望正在消失。这种失望提醒人们默克在本十年结束前面临的挑战：Keytruda 失去了专利保护，Keytruda 是一款癌症药物，约占其收入的三分之一。默克一直在努力填补这一空白。莫努匹拉韦似乎不会对这一努力做出重大贡献。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110395878","content_text":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.\nThe Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.\nThe authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.\nAs Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.\nInvestors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.\nAnd the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.\nThe good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.\nThe FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.\nEarlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3327,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698109374"}